Sino Biopharmaceutical Limited 1177
HKEX · Hong Kong SAR China · Health Technology
HKD 5.71+0.16 (+2.88%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Sino Biopharmaceutical Limited (HKEX: 01177), a leading innovation-driven pharmaceutical company in China, announced the launch of its new global brand, SBP Group, during its interim results meeting. SBP stands for Science, Breakthroughs and Patients: Science is where the company starts; breakthroughs are what it pursues; patients are why it does what it does. This philosophy aligns with the Company's mission, "Science for a Healthier World."
Sino Biopharmaceutical will receive an upfront payment of $200m from AstraZeneca.
The European stock markets closed sharply lower in Wednesday trading after fighting between the US a
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.